Advanced search
Publication Cover
Molecular & Cellular Oncology Volume 5, 2018 - Issue 4
Submit an article Journal homepage
1,757
Views
1
CrossRef citations to date
0
Altmetric
Author's Views

DDR1 inhibition as a new therapeutic strategy for colorectal cancer

Audrey SirventCentre de Recherche en Biologie cellulaire de Montpellier (CRBM), Univ Montpellier, CNRS1919 Route de Mende, 34293 Montpellier, France.Correspondence[email protected] [email protected] [email protected]
ORCID Iconhttp://orcid.org/0000-0003-4555-6312View further author information
ORCID Icon,
Marie LafitteCentre de Recherche en Biologie cellulaire de Montpellier (CRBM), Univ Montpellier, CNRS1919 Route de Mende, 34293 Montpellier, France.ORCID Iconhttp://orcid.org/0000-0003-2026-855XView further author information
ORCID Icon &
Serge RocheCentre de Recherche en Biologie cellulaire de Montpellier (CRBM), Univ Montpellier, CNRS1919 Route de Mende, 34293 Montpellier, France.Correspondence[email protected] [email protected] [email protected]
View further author information
Article: e1465882 | Received 11 Apr 2018, Accepted 13 Apr 2018, Published online: 23 Jul 2018

References

  • Vanharanta S, Massagué J. Origins of Metastatic Traits. Cancer Cell. 2013;24(4):410–21. doi:10.1016/j.ccr.2013.09.007.
  • Zhang Z, Wang Y, Zhang J, Zhong J, Yang R. COL1A1 promotes metastasis in colorectal cancer by regulating the WNT/PCP pathway. Mol Med Rep. 2018;17(4):5037–42. doi:10.3892/mmr.2018.8533.
  • Leitinger B. Discoidin domain receptor functions in physiological and pathological conditions. Int Rev Cell Mol Biol. 2014;310:39–87. doi:10.1016/B978-0-12-800180-6.00002-5.
  • Rammal H, Saby C, Magnien K, Van-Gulick L, Garnotel R, Buache E, El Btaouri H, Jeannesson P, Morjani H. Discoidin Domain Receptors: Potential Actors and Targets in Cancer. Front Pharmacol. 2016. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4789497/
  • Gao H, Chakraborty G, Zhang Z, Akalay I, Gadiya M, Gao Y, Sinha S, Hu J, Jiang C, Akram M, et al. Multi-organ Site Metastatic Reactivation Mediated by Non-canonical Discoidin Domain Receptor 1 Signaling. Cell. 2016;166(1):47–62. doi:10.1016/j.cell.2016.06.009.
  • Ambrogio C, Nadal E, Villanueva A, Gómez-López G, Cash TP, Barbacid M, Santamaría D. KRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapy. ESMO Open. 2016. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070278/. doi:10.1136/esmoopen-2016-000076. PMID:27843638
  • Jeitany M, Leroy C, Tosti P, Lafitte M, Guet JL, Simon V, Bonenfant D, Robert B, Grillet F, Mollevi C, et al. Inhibition of DDR1‐BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer. EMBO Mol Med. 2018;10(4): e7918. doi:10.15252/emmm.201707918. PMID:29438985
  • Weisberg E, Manley PW, Breitenstein W, Brüggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7(2):129–41. doi:10.1016/j.ccr.2005.01.007.
  • Rix U, Hantschel O, Dürnberger G, Rix LLR, Planyavsky M, Fernbach NV, Kaupe I, Bennett KL, Valent P, Colinge J, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood. 2007;110(12):4055–63. doi:10.1182/blood-2007-07-102061.
  • Grillet F, Bayet E, Villeronce O, Zappia L, Lagerqvist EL, Lunke S, Charafe-Jauffret E, Pham K, Molck C, Rolland N, et al. Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks in ex vivo culture. Gut. 2017;66(10):1802–10. doi:10.1136/gutjnl-2016-311447

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.